Virginia wins AstraZeneca megafactory over Maryland

"There's going to be so much losing, you'll get tired of losing." We're definitely tired of losing in Montgomery County and Maryland, but Virginia just handed us another big L. Pharmaceutical giant AstraZeneca has announced it plans to build its largest global drug manufacturing facility yet in Virginia. The loss is even harder to take when you consider that AstraZeneca already has a substantial presence here in Montgomery County. How did we lose this one?

AstraZeneca's announcement is the latest victory for President Donald Trump's trade strategy, which is in part designed to bring jobs back to America. GE Appliances recently announced it would relocate some of its China manufacturing footprint to the massive factory complex at Appliance Park in Louisville, Kentucky. AstraZeneca's move is to avoid high tariffs Trump proposed for drug imports. 

Montgomery County isn't a total loser in the $50 billion investment AstraZeneca plans to make in the U.S. over the next five years: the company said it also plans to expand its Gaithersburg manufacturing facility, and to add a cell therapy manufacturing facility in Rockville. But it's simply cheaper to do business in Virginia, and the Commonwealth is quickly catching up in the regional biotech race, which has been the sole bright spot in Montgomery County's otherwise-moribund economy.

“I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States,” Virginia Governor Glenn Youngkin said in a statement. “This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”  

“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,” AstraZeneca Chief Executive Officer Pascal Soriot said. “It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”